Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas R Macgregor

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
HIV Clinical Trials|November 29, 2007
Case-control exploration of relationships between early rash or liver toxicity and plasma concentrations of nevirapine and primary metabolitesDavid B Hall, Thomas R Macgregor
Antimicrobial Agents and Chemotherapy|October 1, 2008
Pharmacokinetic and safety evaluation of BILR 355, a second-generation nonnucleoside reverse transcriptase inhibitor, in healthy volunteersFenglei Huang, Michael Koenen-Bergmann, Thomas R Macgregor, et al.
HIV Clinical Trials|February 1, 2005
Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteersThomas R MacGregor, John P Sabo, Stephen H Norris, et al.
Journal of Clinical Pharmacology|October 2, 2009
Assessment of nevirapine bioavailability from targeted sites in the human gastrointestinal tractSreeraj Macha, Chan-Loi Yong, Thomas R MacGregor, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|July 10, 2007
Quantitation of five nevirapine oxidative metabolites in human plasma using liquid chromatography-tandem mass spectrometryLois S Rowland, Thomas R MacGregor, Scot J Campbell, et al.
Antiviral Therapy|March 9, 2005
Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN studyBregt S Kappelhoff, Frank van Leth, Thomas R MacGregor, et al.
Biopharmaceutics & Drug Disposition|October 31, 2009
In vitro-in vivo correlation for nevirapine extended release tabletsSreeraj Macha, Chan-Loi Yong, Todd Darrington, et al.
Antimicrobial Agents and Chemotherapy|July 22, 2009
Pharmacokinetic assessment of nevirapine and metabolites in human immunodeficiency virus type 1-infected patients with hepatic fibrosisAnna Maria Cammett, Thomas R MacGregor, Jan M Wruck, et al.
Journal of Clinical Pharmacology|August 14, 2013
Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetesMatthew M Riggs, Alexander Staab, Leo Seman, et al.
HIV Clinical Trials|April 20, 2010
Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patientsFrank D Goebel, Thomas R MacGregor, John P Sabo, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
HIV Clinical Trials|November 29, 2007
Case-control exploration of relationships between early rash or liver toxicity and plasma concentrations of nevirapine and primary metabolitesDavid B Hall, Thomas R Macgregor
Antimicrobial Agents and Chemotherapy|October 1, 2008
Pharmacokinetic and safety evaluation of BILR 355, a second-generation nonnucleoside reverse transcriptase inhibitor, in healthy volunteersFenglei Huang, Michael Koenen-Bergmann, Thomas R Macgregor, et al.
HIV Clinical Trials|February 1, 2005
Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteersThomas R MacGregor, John P Sabo, Stephen H Norris, et al.
Journal of Clinical Pharmacology|October 2, 2009
Assessment of nevirapine bioavailability from targeted sites in the human gastrointestinal tractSreeraj Macha, Chan-Loi Yong, Thomas R MacGregor, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|July 10, 2007
Quantitation of five nevirapine oxidative metabolites in human plasma using liquid chromatography-tandem mass spectrometryLois S Rowland, Thomas R MacGregor, Scot J Campbell, et al.
Antiviral Therapy|March 9, 2005
Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN studyBregt S Kappelhoff, Frank van Leth, Thomas R MacGregor, et al.
Biopharmaceutics & Drug Disposition|October 31, 2009
In vitro-in vivo correlation for nevirapine extended release tabletsSreeraj Macha, Chan-Loi Yong, Todd Darrington, et al.
Antimicrobial Agents and Chemotherapy|July 22, 2009
Pharmacokinetic assessment of nevirapine and metabolites in human immunodeficiency virus type 1-infected patients with hepatic fibrosisAnna Maria Cammett, Thomas R MacGregor, Jan M Wruck, et al.
Journal of Clinical Pharmacology|August 14, 2013
Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetesMatthew M Riggs, Alexander Staab, Leo Seman, et al.
HIV Clinical Trials|April 20, 2010
Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patientsFrank D Goebel, Thomas R MacGregor, John P Sabo, et al.
Pageof 3